I have a small position and believe their technology has alot of potential. Unfortunately, like most small cap biotech stocks these days, they are underfunded and will either be forced to dilute existing shareholders even more than they already are, or bring in a partner on less than ideal terms (simply because they have no negotiating leverage). I took my position earlier in the year with the hope that they would just sell the company - now, I'll let it ride with the hopes that they sell or secure a partnership after the phase II combination data for TH-302 is revealed, which I think will be sometime early next year?
These are not insiders buys, the information just represents the change in the number of shares from the split.
Unfortunately, the 23 cent decline today is real. THLD is now almost $1.00 below the warrant price. I sure hope those "insiders" know whether or not TH302, 2DG work, otherwise they can kiss another $18 million goodbye.